Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
Authors
Keywords
Biomarker, Expanded access programme, Ipilimumab, Long-term survival, Metastatic melanoma
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 62, Issue 6, Pages 1021-1028
Publisher
Springer Nature
Online
2013-04-16
DOI
10.1007/s00262-013-1418-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports
- (2012) Sofie Wilgenhof et al. CANCER INVESTIGATION
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
- (2012) P. A. Prieto et al. CLINICAL CANCER RESEARCH
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
- (2012) Wenshi Wang et al. Journal of Translational Medicine
- Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
- (2011) Riccardo Danielli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
- (2011) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Advances in systemic treatment of melanoma
- (2010) A. M. M. Eggermont ANNALS OF ONCOLOGY
- Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer
- (2010) Xin An et al. BIOMARKERS
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- (2010) Geoffrey Y. Ku et al. CANCER
- Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
- (2010) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Estimates of cancer incidence and mortality in Europe in 2008
- (2010) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Effector Functions of Donor-Reactive CD8 Memory T Cells Are Dependent on ICOS Induced During Division in Cardiac Grafts
- (2008) A. D. Schenk et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
- (2008) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- Neutrophil/lymphocyte ratio and its association with survival after complete resection in non–small cell lung cancer
- (2008) Khaled M. Sarraf et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now